Sort by
Refine Your Search
-
Programmed Cell Death-1 (PD-1). PD-1 targeted therapies elicit clinical responses in different cancertypes, but response rates are rarely above 20%. Positive outcomes have been associated with CD8T cell
-
, the transient conformations exposed during folding might provide good targets for binding of small molecules, with more specificity than the targets presented by the final functional state. Goals. The key
-
contributions to geometry and dynamical systems. The targeted profile covers real and complex analysis, harmonic analysis, analysis of PDEs for geometry, contributions of analysis to the following areas: theory
-
target regions of interest (e.g interface between parasite and host cell organelles) for FIB milling and cryoET data collection. Phase contrast tomography of these samples is already providing
-
to target the mechanistic alterations at the basis of resistance to current therapeutic options. The research program will favor translational approach and the experimental design will benefit from
-
attack. Our ultimate goal is to uncover novel therapeutic targets that can enhance the efficacy of anticancer immunotherapies. A major barrier to effective immunotherapy is tumor immune evasion. We have
-
the boundaries of cellular reprogramming by introducing scalable computational methods that streamline the discovery of reprogramming targets and control strategies. A key innovation of EdgeCR is its
-
Virtual laboratory to predict the ability of a fluctuating biomass to satisfy a material use-VARIOUS
and organic waste) of which the properties are different and subject to seasonal and climatic variations. For the bioeconomy, it is therefore necessary to sort biomass sources according to the target
-
, its features, or the actual model parameters, to (ii) poisoning attacks that target the integrity of the ML model and cause a general degradation of the performance of the model
-
the forefront of translational cancer research, with a strategic focus on discovering druggable gene targets and key signaling pathways in the tumor microenvironment. Our aim is to reprogram immunologically “cold